A practical reference on 非天然氨基酸: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-21 and is reviewed periodically as new material appears.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
Charles III and Camilla attend the King's first Royal Maundy Service at York Minster, where he distributes Maundy money to pensioners. 7 April The Foreign and Commonwealth Office confirms that two British-Israeli sisters in their 20s have been killed during a shooting attack on their car in the northern West Bank. Their mother, also injured in the incident, dies on 10 April. The Bank of England announces that they have begun printing Series G banknotes featuring King Charles III. No additional changes are made to the existing designs of £5, £10, £20 and £50 notes, which will enter circulation from mid-2024. 10 April – Coronation of Charles III and Camilla: Buckingham Palace confirms that King Charles III and Queen Camilla will travel to Westminster in the more modern Diamond Jubilee State Coach for the coronation, before returning to Buckingham Palace in the more traditional Gold State Coach. 11 April The CBI, one of the UK's largest business groups, dismisses Director-General Tony Danker following complaints about his conduct involving a female employee. Rain Newton-Smith, who served as the CBI's chief economist until March 2023, is appointed to replace Danker. The International Monetary Fund predicts that the UK economy will be among the worst performing in the G20 nations during 2023. US president Joe Biden arrives in Belfast to mark the 25th anniversary of the Good Friday Agreement. 12 April The Scottish Government announces it will mount a legal challenge against the UK government's decision to block the Gender Recognition Reform (Scotland) Bill.
== Use as a lipid biomarker == Tetrahymanol has been found in many marine ciliates at relatively high concentrations, suggesting it may be a useful biomarker in the Earth's rock record. During diagenesis, the alcohol functional group is lost and tetrahymanol becomes gammacerane. Like other saturated triterpenoid skeletons, gammacerane is a highly stable molecule that can preserved in rocks on geological timescales. The oldest gammacerane biomarker was found in a rock 850 million years old. Based on microbial physiology studies, gammacerane was suggested as a potential biomarker for ocean stratification. When water columns stratify, anoxic conditions can form in the bottom waters. Ciliates living in these conditions must adapt to produce lipids that do not require molecular oxygen for their biosynthesis. A direct correlation between sterol availability and tetrahymanol synthesis in ciliates has been shown, leading to the hypothesis that gammacerane in sediments is a biomarker for ocean stratification. This hypothesis was later met with skepticism. While tetrahymanol had mostly been observed in ciliates, several bacteria were then shown to synthesize the lipid and many bacteria across multiple phyla had the gene for tetrahymanol synthase. This evidence has been used to question the potential of gammacerane as a biomarker for water column stratification. For instance, aerobic methanotrophic bacteria were shown to synthesize tetrahymanol. Thus it is not solely a response to anoxic environments.
== Use in diagnostic tests == Fecal elastase is an enzyme originally thought to be pancreatic elastase 1 (CELA1), but this was discovered to be an error, and it is actually likely be CELA3B. Fecal elastase is not degraded in intestinal transit, so that its concentration in feces reflects exocrine pancreatic function. In inflammation of the pancreas, fecal elastase is released into the bloodstream. Thus the quantification of fecal elastase in serum allows diagnosis or exclusion of acute pancreatitis. Main indications:
Arthur 'Blaine' Bowman (born 1946 in Ogden, Utah, USA) is a leading proponent of ion chromatography, who has served variously as chairman, president, chief executive officer, and director of Dionex Corporation, a manufacturer of analytical instruments. Bowman received the 2015 Pittcon Heritage Award in recognition of his contributions to the field of ion chromatography.
There may be flocculation in some gels, which may produce an unstable gel. The rheology of some gels are easily altered by environmental factors such as temperature and humidity, resulting in stricter storage requirements. Syneresis of the gel may occur during storage, causing the gel to shrink unpredictably or even dry out. The gelators may precipitate and salt out, and some drugs may degrade in gel formulation due to the other ingredients present in the formulation. Some additives and gelators added into the formulation may cause irritation problems, such as skin irritation, dermatitis or allergic conditions. The increased water content in gels increases the chances of bacterial or fungal attack, which may contaminate the gel, making it unsuitable for use. Considering the direct route of administration, drugs must be very small in size to have an effective plasma concentration for action. The particle size and other properties of the drug may also affect its absorption through the skin barrier, resulting in an unreliable effect.
Sources: en.wikipedia.org
== Markers == CAFs produce a number of proteins that are specific to the origin of the cells. However, as there are no specific protein to CAFs, a combination of these proteins are then used as markers to identify CAFs High levels of the marker would mean a low prognosis due to the stage of cancer.
=== SARM1 === SARM1 is a Toll-like receptor protein and also functions as a intracellular NADase. Under normal circumstances NADase activity are inhibited in the presence of NAD+, where NAD+ binds to armadillo/heat motifs (ARMs), which inhibits the dimerization of the toll-like receptor domain that activates the NADase activity. If there are damages to the binding site of NAD+ or disruption that prevents the interaction between ARMs and the toll-like receptor domain, NADase activity will be turned on at a constitutive level. As a result SARM1 will have higher consumption of NAD+ and produce NADase products (ADP-ribose and nicotinamide) rather than the production of cADPR from ADP-ribosyl cyclase.
Like the East German state newspaper, official Romanian news organs made no mention of the fall of the Berlin Wall in the first days following 9 November 1989. The most notable news in Romanian newspapers of 11 November 1989, was the "masterly lecture by comrade Nicolae Ceaușescu at the extended plenary session of the Central Committee of the Communist Party of Romania," in which the Romanian head of state and party highly praised the "brilliant programme for the work and revolutionary struggle of all our people," as well as the "exemplary fulfillment of economic tasks." What had happened 1,500 km (930 mi) northwest of Bucharest, in divided Berlin, during those days is not even mentioned. Socialism is praised as the "way of the free, independent development of the peoples." The same day, on Bucharest's Brezoianu Street and Kogălniceanu Boulevard, a group of students from Cluj-Napoca attempted a demonstration but were quickly apprehended. It initially appeared that Ceaușescu would weather the wave of revolution sweeping across Eastern Europe, as he was formally re-elected for another five-year term as General Secretary of the Romanian Communist Party on 24 November at the party's XIV Congress. On that same day, Ceaușescu's counterpart in Czechoslovakia, Miloš Jakeš, resigned along with the entire Communist leadership, effectively ending Communist rule in Czechoslovakia.
By the end of the 1990s, marketing and products began to take on a more retro approach. Former menu items, such as the Burger Family, were reintroduced, and marketing became more targeted toward the baby boomer generation. The Great Root Bear and (in English Canada) the "ba-dum ba-dum" theme were also retired from most advertising (the tuba theme is still used in French-language ads). A new restaurant design was introduced, featuring a bright orange and yellow exterior, reminiscent of the 1950s, while the interior is decorated with memorabilia associated with the same period. Existing restaurants were renovated to match the new style. Meanwhile, with malls in decline, A&W began to focus on opening new standalone restaurants, particularly in smaller markets where McDonald's was often the only major hamburger chain. The last drive-in style restaurant closed in 2000, in Langley, British Columbia.
UR-AK49 is a drug used in scientific research which acts as a potent antagonist for the Neuropeptide Y / Pancreatic polypeptide receptor Y4, and also as a partial agonist at the histamine receptors H1 and H2. UR-AK49 is a pure antagonist at Y4 with no partial agonist effects, and although it is only slightly selective for Y4 over the related Y1 and Y5 receptors, as the first non-peptide Y4 antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.